# INT-101-01 (NCT05434234)

> A Study of YL201 in Patients With Advanced Solid Tumors

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05434234
- Phase: PHASE1, PHASE2
- Status: RECRUITING
- Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.
- Conditions: Advanced Solid Tumor
- Interventions: YL201; YL201; YL201 and atezolizumab
- Enrollment: 312
- Primary outcome: Evaluate the occurrence of DLTs during the first cycle in Part 1
- Primary outcome: Evaluate the AEs in Part 2 as characterized by type, frequency, severity, timing, seriousness and relationship to study treatment
- Primary outcome: Evaluate the prostate-specific antigen (PSA) response rate for patients with prostate cancer in Part 2
- Primary outcome: Evaluate the objective response rate (ORR) for patients with solid tumors other than prostate cancer in Part 2, assessed using RECIST version 1.1
- Primary outcome: Laboratory abnormalities as characterized by type, frequency, severity, and timing in Part 2
- Primary outcome: Incidence, nature, and severity of AEs graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) V5.0 in Part 3
- Primary outcome: Nature and frequency of dose-limiting toxicities (DLTs), incidence, nature, and severity of laboratory abnormalities in Part 3

## Indexed commentary on INT-101-01 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=int-101-01-nct05434234